更新于：2024-11-21

Cadralazine

卡屈嗪

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

Cadralazine (JP17/INN)

+ [3]

靶点-

作用机制-

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C12H21N5O3

InChIKeyQLTVVOATEHFXLT-UHFFFAOYSA-N

CAS号64241-34-5

关联

100 项与卡屈嗪相关的临床结果

登录后查看更多信息

100 项与卡屈嗪相关的转化医学

登录后查看更多信息

100 项与卡屈嗪相关的专利（医药）

登录后查看更多信息

项与卡屈嗪相关的文献（医药）

2012-01-01·Journal of Biopharmaceutical Statistics4区 · 医学

An Estimation Method of the Clearance for a One-Compartment Model of a Single Bolus Intravenous Injection by a Single Sampling

4区 · 医学

Article

作者: Funatogawa, Takashi ; Funatogawa, Ikuko

In clinical trials, sometimes only a single drug concentration can be measured from a patient, because of the burden on the patient. From a single concentration, we cannot generally obtain point estimates of each pharmacokinetic parameter in a patient. In this article, we propose a method to estimate the clearance using a one-compartment model of a single-bolus intravenous injection from a single concentration at a sampling point between 1.5 and 2.5 half-lives. This method requires an assumed value for the volume of distribution but is robust to misspecification. This approach is illustrated by simulated concentration data and cadralazine concentration data.

1999-01-01·Japanese Heart Journal

Different Effects of Temocapril and Cadralazine on Electrocardiographic Voltages and Left Ventricular Mass in Patients with Essential Hypertension.

Article

作者: TAKATA, Masanobu ; INOUE, Hiroshi ; TOMODA, Fumihiro ; YASUMOTO, Kotaro ; TOMITA, Shin ; UENO, Hitoshi

To assess whether electrocardiographic variables are useful to detect the regression of left ventricular (LV) mass after long-term antihypertensive treatment, we related electrocardiographic voltages to echocardiographic variables before and after treatment with an ACE inhibitor, temocapril (TEM), or direct vasodilator, cadralazine (CAD). Twenty-one patients with essential hypertension were treated with either TEM (n = 11) or CAD (n = 10) for one year. LV mass index (LVMI) by echocardiography and Sokolow-Lyon voltage (SV1 + RV5), Cornell voltage (RaVL + SV3) and RV5 + RV6 by standard 12-lead electrocardiographic voltages were determined before and after treatment. Both drugs decreased blood pressure to the same extent. Both Sokolow-Lyon voltage and RV5 + RV6 tended to decrease in the ACE group (40.0 +/- 9.4 to 37.2 +/- 9.4 mm and 44.7 +/- 13.5 to 41.7 +/- 11.7 mm, respectively, N.S.), but not in the CAD group (38.4 +/- 6.8 to 39.7 +/- 7.7 mm and 42.9 +/- 10.4 to 46.8 +/- 11.2 mm, respectively, N.S.). LVMI decreased in the ACE group (-24 +/- 22 g/m2), whereas it increased in the CAD group (37 +/- 27 g/m2, p < 0.01). Change in LVMI was correlated with the changes in RV5 + RV6 and Sokolow-Lyon voltage (r = 0.73, p < 0.01 and r = 0.70, p < 0.01, respectively), but not with that in Cornell voltage. These results indicated that the changes in voltage criteria of RV5 + RV6 and Sokolow-Lyon are useful to assess the change in LVM after antihypertensive treatment in patients with essential hypertension although voltage variables in electrocardiogram were not sensitive to detect changes in LVMI.

1997-11-01·Journal of Cardiovascular Pharmacology4区 · 医学

The Effects of Long-Term Treatment on Left Ventricular Hypertrophy in Patients with Essential Hypertension: Relation to Changes in Neurohumoral Factors

4区 · 医学

Article

作者: Takata, Masanobu ; Oh-hassi, Shinya ; Yasumoto, Kotaro ; Ueno, Hitoshi ; Tomita, Shin ; Inoue, Hiroshi

This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension. Furthermore, to elucidate the mechanism responsible for regression of LV hypertrophy after treatment, LV mass index (LVMI) by echocardiography, plasma renin activity (PRA), aldosterone (PAC), norepinephrine, and atrial natriuretic peptide (ANP) concentration were measured before and after treatment. Thirty-six patients were randomly assigned to the NIL, TEM, or CAD groups. Blood pressure (BP) before treatment was 174 +/- 10/104 +/- 7, 173 +/- 18/103 +/- 8, and 171 +/- 16/103 +/- 7 mm Hg (mean +/- SD) in NIL, TEM, and CAD groups, respectively. BP was lower after treatment with each of the three test drugs than after the placebo period, and there were no differences in BP reduction among three groups. LVMI, in NIL and TEM, was reduced from 129 +/- 48 to 115 +/- 39 g/m2 and from 117 +/- 39 to 88 +/- 20 g/m2 (p < 0.05 and p < 0.01, respectively), whereas, in the CAD group, it was increased (110 +/- 30 to 138 +/- 27 g/m2; p < 0.01). In the CAD group, PAC decreased and ANP increased significantly. The change in LVMI correlated with that in BP for TEM and with that in ANP in all patients. These data indicated that LV volume overload as well as LV pressure overload may contribute to LV hypertrophy and that monotherapy with CAD is not desirable from the point of view of LV mass reduction in essential hypertension.

100 项与卡屈嗪相关的药物交易

登录后查看更多信息